Errico Federico Perillo

Errico Federico Perillo


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2023 in Cardiogenetics
Verified
Journal Article
Open access
PDF file
FBFelice Borrelli
Felice Borrelli
Maria-Angela LosiMaria-Angela Losi
Maria-Angela Losi
GCGrazia Canciello
Grazia Canciello
GTGaetano Todde
Gaetano Todde
EPErrico Federico Perillo
Errico Federico Perillo
RLRaffaella Lombardi
Raffaella Lombardi
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiovascular disorder and is characterized by left ventricular hypertrophy (LVH), which is unexplained by abnormal loading conditions. HCM is inherited as an autosomal dominant trait and, in about 40% of patients, the causal mutation is identified in genes encoding sarcomere proteins. According to the results of genetic screening, HCM patients are currently categorized in two main sub-populations: sarcomeric-positive (Sarc+) patients, in whom the causal mutation is identified in a sarcomeric gene; and sarcomeric-negative (Sarc−) patients, in whom a causal mutation has not been identified. In rare cases, Sarc− HCM cases may be caused by pathogenic variants in non-sarcomeric genes. The aim of this review is to describe the differences in the phenotypic expression and clinical outcomes of Sarc+ and Sarc− HCM and to briefly discuss the current knowledge about HCM caused by rare non-sarcomeric mutations.

25 May 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
EPErrico Federico Perillo
Errico Federico Perillo
GCGrazia Canciello
Grazia Canciello
FBFelice Borrelli
Felice Borrelli
GTGaetano Todde
Gaetano Todde
MIMassimo Imbriaco
Massimo Imbriaco
Maria-Angela LosiMaria-Angela Losi
Maria-Angela Losi
Hypertrophic cardiomyopathy (HCM) is a genetic disease with heterogeneous clinical presentation and prognosis. Within the broad phenotypic expression of HCM, there is a subgroup of patients with a left ventricular (LV) apical aneurysm, which has an estimated prevalence between 2% and 5%. LV apical aneurysm is characterized by an area of apical dyskinesis or akinesis, often associated with regional scarring. To date, the most accepted pathomechanism of this complication is, in absence of coronary artery disease, the high systolic intra-aneurysmal pressure, which, combined with impaired diastolic perfusion from lower stroke volume, results in supply–demand ischemia and myocardial injury. Apical aneurysm is increasingly recognized as a poor prognostic marker; however, the efficacy of prophylactic anticoagulation and/or intracardiac cardioverted defibrillator (ICD) in improving morbidity and mortality is not yet clearly demonstrated. This review aims to elucidate the mechanism, diagnosis and clinical implication of LV aneurysm in patients with HCM.

15 May 2023 in Cardiogenetics
Verified
Journal Article
Open access
PDF file
GTGaetano Todde
Gaetano Todde
GCGrazia Canciello
Grazia Canciello
FBFelice Borrelli
Felice Borrelli
EPErrico Federico Perillo
Errico Federico Perillo
GEGiovanni Esposito
Giovanni Esposito
Maria-Angela LosiMaria-Angela Losi
Maria-Angela Losi
Left ventricular outflow obstruction (LVOTO) and diastolic dysfunction are the main pathophysiological characteristics of hypertrophic cardiomyopathy (HCM)LVOTO, may be identified in more than half of HCM patients and represents an important determinant of symptoms and a predictor of worse prognosis. This review aims to clarify the LVOTO mechanism in, diagnosis of, and therapeutic strategies for patients with obstructive HCM.